Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:ARTH NASDAQ:PAVM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARTHArch Therapeutics$0.00$0.16▼$1.57$763K4.024,068 shsN/APAVMPAVmed$8.05-1.0%$9.67$6.00▼$28.44$8.09M0.6413,332 shs4,036 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARTHArch Therapeutics0.00%0.00%0.00%0.00%-99.25%PAVMPAVmed0.00%+1.55%-13.40%-10.87%-64.01%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARTHArch Therapeutics$0.00$0.16▼$1.57$763K4.024,068 shsN/APAVMPAVmed$8.05-1.0%$9.67$6.00▼$28.44$8.09M0.6413,332 shs4,036 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARTHArch Therapeutics0.00%0.00%0.00%0.00%-99.25%PAVMPAVmed0.00%+1.55%-13.40%-10.87%-64.01%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARTHArch Therapeutics 0.00N/AN/AN/APAVMPAVmed 2.00Hold$65.00707.45% UpsideCurrent Analyst Ratings BreakdownLatest ARTH and PAVM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/21/2026PAVMPAVmed Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)4/9/2026PAVMPAVmed Ascendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$510.00 ➝ $65.00(Data available from 5/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARTHArch Therapeutics$80K0.00N/AN/A($2.43) per share0.00PAVMPAVmed$70K115.00N/AN/A($2.42) per share-3.33Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARTHArch Therapeutics-$6.98M-$2.34N/AN/AN/A-8,257.70%N/A-730.22%N/APAVMPAVmed$400K-$22.77N/AN/AN/A564.79%-242.99%-17.25%5/15/2026 (Estimated)Latest ARTH and PAVM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026PAVMPAVmed-$0.69N/AN/AN/A$0.07 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthARTHArch TherapeuticsN/AN/AN/AN/AN/APAVMPAVmedN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARTHArch TherapeuticsN/A0.100.01PAVMPAVmedN/A0.170.17Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARTHArch Therapeutics6.91%PAVMPAVmed19.93%Insider OwnershipCompanyInsider OwnershipARTHArch Therapeutics4.50%PAVMPAVmed5.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARTHArch Therapeutics104.74 million4.53 millionNot OptionablePAVMPAVmed901.00 million938,000OptionableARTH and PAVM HeadlinesRecent News About These CompaniesPAVmed to Hold First Quarter 2026 Business Update Conference Call and Webcast on May 15, 2026May 1, 2026 | prnewswire.comLucid Diagnostics to Hold First Quarter 2026 Business Update Conference Call and Webcast on May 14, 2026April 30, 2026 | prnewswire.comPAVmed (PAVM) price target decreased by 84.60% to 41.31April 29, 2026 | msn.comWhy The PAVmed (PAVM) Story Is Shifting After A Major Valuation ResetApril 27, 2026 | finance.yahoo.comLucid Diagnostics Announces Closing of $18 Million Underwritten Offering of Common StockApril 24, 2026 | prnewswire.comLucid Diagnostics Announces $18 Million Underwritten Offering of Common StockApril 23, 2026 | prnewswire.comPAVmed (PAVM) price target decreased by 16.51% to 268.26April 10, 2026 | msn.comLucid Diagnostics to Participate in Fireside Chat at the 25th Annual Needham Virtual Healthcare ConferenceApril 9, 2026 | prnewswire.comHow The PAVmed (PAVM) Narrative Is Shifting After The Latest Analyst ReassessmentApril 9, 2026 | finance.yahoo.comPAVM Assigns Joseph Virgilio to Lead Medical Device Portfolio RelaunchApril 7, 2026 | zacks.comPavmed relaunches medical device portfolio with new headApril 3, 2026 | massdevice.comPAVmed Appoints Joseph Virgilio to Lead Relaunched Medical Device PortfolioApril 2, 2026 | prnewswire.comPAVmed Inc. Q4 2025 Earnings Call SummaryApril 1, 2026 | finance.yahoo.comPAVmed Inc. (NASDAQ:PAVM) Q4 2025 earnings call transcriptApril 1, 2026 | msn.comPAVmed Inc.: PAVmed Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial ResultsMarch 30, 2026 | finanznachrichten.dePAVmed Inc (PAVM) Q4 2025 Earnings Call Highlights: Strategic Restructuring and Growth InitiativesMarch 30, 2026 | uk.finance.yahoo.comPAVmed Inc. (PAVM) Q4 2025 Earnings Call TranscriptMarch 30, 2026 | seekingalpha.comPAVmed (PAVM) Upgraded to Buy: Here's What You Should KnowMarch 30, 2026 | zacks.comPAVmed Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial ResultsMarch 30, 2026 | prnewswire.comWhat To Expect From PAVmed Inc (PAVM) Q4 2025 EarningsMarch 27, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeARTH and PAVM Company DescriptionsArch Therapeutics OTCMKTS:ARTHArch Therapeutics, Inc., together with its subsidiaries, operates as a biotechnology company in the United States. It develops and markets products based on its AC5 self-assembling technology platform to stop bleeding and control leaking, as well as manages wounds during surgery, trauma, and interventional care or from disease. The company's flagship products include AC5 advanced wound system and AC5 topical hemostat, which are intended for skin applications, such as management of complicated chronic wounds or acute surgical wounds. It is also involved in the development of AC5-G for gastrointestinal endoscopic procedures, and AC5-V and AC5 surgical hemostat for hemostasis inside the body. The company was founded in 2006 and is based in Framingham, Massachusetts.PAVmed NASDAQ:PAVM$8.05 -0.08 (-0.98%) Closing price 04:00 PM EasternExtended Trading$8.11 +0.06 (+0.75%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.PAVmed Inc. focuses on acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck. Its product pipeline also comprises EsoCure EsoCure Esophageal Ablation Device for treating dysplastic BE; PortIO, an implantable intraosseous vascular access device; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir Drops After a Blowout Q1—What Investors Should Know Shopify’s Valuation Crisis Creates Opportunity in 2026 onsemi Stock Dips After Earnings: Why the Dip Is Buyable TSLA: 3 Reasons the Stock Could Hit $400 in May Nebius Breaks Out to All-Time Highs—Here's What's Driving It. 3 Reasons Analysts Love DexCom The Great Chip Divide: AI Chip War Pivots from Hype to Execution Atomic Dividends: Big Tech's New Energy Bet Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
